Condition
Infection Due to Resistant Organism
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Terminated1
Unknown1
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02922816Phase 1TerminatedPrimary
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
NCT02816437Phase 1WithdrawnPrimary
FMT for MDRO Colonization in Solid Organ Transplant
NCT01659515UnknownPrimary
Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
Showing all 3 trials